According to multi-industry laboratory company Intertek, it has acquired OINDP testing specialist Melbourn Scientific. In its announcement, Intertek cites Melbourn's "profound expertise in all aspects of characterization of orally inhaled and intra-nasal products (OINDP)" and "an increasing demand worldwide for more patient friendly drug delivery methods for optimum … [Read more...] about Melbourn Scientific acquired by Intertek
News
Trimel’s NDA for intranasal testosterone product accepted by the FDA
Trimel Pharmaceuticals has announced the acceptance of its NDA for CompleoTRT bioadhesive intranasal gel testosterone and the PDUFA date, February 28, 2014. The company announced submission of the NDA at the end of April 2013. According to Trimel, CompleoTRT is an intranasal gel with no smell or taste, delivered using a multi-dose applicator, that will eliminate … [Read more...] about Trimel’s NDA for intranasal testosterone product accepted by the FDA
RDD China cancelled
According to RDD Online, the RDD China meeting scheduled to take place October 16-18, 2013 in Beijing has been cancelled due to "contractual problems which made it impossible for RDD to guarantee the quality of the conference and ensure that all exhibitors and workshop presenters would be treated equitably." The meeting, which was to be co-sponsored by the Chinese … [Read more...] about RDD China cancelled
Prosonix appoints Frank Condella as Non-Executive Director
Inhaled pharmaceuticals company Prosonix has announced the appointment of Columbia Laboratories President and CEO Frank Condella as a Non-executive Director of Prosonix. Condella has held numerous position in the pharmaceutical industry, including as CEO of SkyePharma from 2006 to 2008 and President of European Operations and Managing Director, UK at IVAX Corporation … [Read more...] about Prosonix appoints Frank Condella as Non-Executive Director
Avanir makes deal with OptiNose for intranasal sumatriptan powder
Avanir Pharmaceuticals has paid $20 million up front to OptiNose for an exclusive North American license for development and commercialization of OptiNose's intranasal low-dose sumatriptan powder for the treatment of acute migraines. OptiNose could receive an additional $90 million in milestone payments and, if the product is approved, Avanir will make royalty … [Read more...] about Avanir makes deal with OptiNose for intranasal sumatriptan powder
Jabil completes acquisition of Nypro
Jabil Circuit has announced the completion of its $665 million acquisition of contract plastics manufacturer Nypro, which makes dry powder inhalers and nasal spray pumps for pharmaceutical companies among other products. According to Jabil, it will keep the Nypro name and will absorb approximately 10,000 Nypro employees. Nypro will keep its headquarters in Clinton, … [Read more...] about Jabil completes acquisition of Nypro
Study shows feasibility of nasal dosing of diazepam during seizure
Acorda Therapeutics announced results from a clinical study of the pharmacokinetics, safety, and tolerability of its diazepam nasal spray for the treatment of cluster seizures in epilepsy patients at the recent International Congress of the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE). Over the course of the study, 31 … [Read more...] about Study shows feasibility of nasal dosing of diazepam during seizure
Arikace meets primary endpoint in Phase 3 study
According to Insmed, a Phase 3 study of more than 300 cystic fibrosis patients has demonstrated the non-inferiority of once-daily Arikace inhaled liposomal amikacin to twice-daily TOBI tobramycin inhalation solution, meeting the study's primary endpoint. The company also announced that the FDA has granted Arikace Fast Track and Qualified Infectious Disease Product … [Read more...] about Arikace meets primary endpoint in Phase 3 study
Zogenix to co-promote Migranal nasal spray in US
Zogenix has announced that it has reached an agreement with Valeant to begin selling Migranal dihydroergotamine mesylate nasal spray in the US beginning in late July 2013 and extending initially through the end of 2015. Valeant will pay Zogenix a quarterly service fee based on a percentage of sales exceeding a specified baseline. Zogenix CEO Roger L. Hawley … [Read more...] about Zogenix to co-promote Migranal nasal spray in US
RespiTech gets grant for inhaled pulmonary fibrosis treatment
The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for development of an aerosol anti-fibrotic for the treatment of pulmonary lung fibrosis. The team's research proposal was titled "A tight squeeze: … [Read more...] about RespiTech gets grant for inhaled pulmonary fibrosis treatment